CAR T-cell therapy: Balance of efficacy and safety

[1]  P. Nguyen,et al.  CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  M. Baker,et al.  Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. , 2016, The Journal of clinical investigation.

[3]  H. Kiyoi,et al.  A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration , 2016, Cancer Immunology Research.

[4]  Chan Hyuk Kim,et al.  Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer. , 2016, Angewandte Chemie.

[5]  Christine E Brown,et al.  Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. , 2016, Blood.

[6]  S. Gottschalk,et al.  T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies , 2016, Scientific Reports.

[7]  A. Hatefi,et al.  Progress and problems with the use of suicide genes for targeted cancer therapy. , 2016, Advanced drug delivery reviews.

[8]  Russell M. Gordley,et al.  Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors , 2016, Cell.

[9]  Kole T. Roybal,et al.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.

[10]  D. Lauro,et al.  T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells. , 2016, Cytotherapy.

[11]  Yu Cao,et al.  Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies , 2016, Proceedings of the National Academy of Sciences.

[12]  Chan Hyuk Kim,et al.  Versatile strategy for controlling the specificity and activity of engineered T cells , 2016, Proceedings of the National Academy of Sciences.

[13]  Chih-Yi Chen,et al.  Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma. , 2015, Lung cancer.

[14]  Wendell A. Lim,et al.  Remote control of therapeutic T cells through a small molecule–gated chimeric receptor , 2015, Science.

[15]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[16]  E. Blyth,et al.  Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. , 2015, Cytotherapy.

[17]  S. Riddell,et al.  Engineering CAR-T cells: Design concepts. , 2015, Trends in immunology.

[18]  J. E. Brewer,et al.  NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma , 2015, Nature Medicine.

[19]  R. Govindan,et al.  Genomic alterations in lung adenocarcinoma. , 2015, The Lancet. Oncology.

[20]  Michel Sadelain,et al.  The pharmacology of second-generation chimeric antigen receptors , 2015, Nature Reviews Drug Discovery.

[21]  S. Mineishi,et al.  Seatbelts in CAR therapy: How Safe Are CARS? , 2015, Pharmaceuticals.

[22]  M. Brown,et al.  Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. , 2015, Cytotherapy.

[23]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[25]  Jen Jen Yeh,et al.  Local iontophoretic administration of cytotoxic therapies to solid tumors , 2015, Science Translational Medicine.

[26]  L. Walker,et al.  Confusing signals: Recent progress in CTLA-4 biology , 2015, Trends in immunology.

[27]  D. Ecker,et al.  The therapeutic monoclonal antibody market , 2015, mAbs.

[28]  F. Goldman,et al.  Improving the safety of cell therapy products by suicide gene transfer , 2014, Front. Pharmacol..

[29]  J. Szöllősi,et al.  TCRs Genetically Linked to CD28 and CD3ε Do Not Mispair with Endogenous TCR Chains and Mediate Enhanced T Cell Persistence and Anti-Melanoma Activity , 2014, The Journal of Immunology.

[30]  A. Snook,et al.  Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer. , 2014, Discovery medicine.

[31]  S. Riddell,et al.  Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells , 2014, Cancer Immunology Research.

[32]  M. Brown,et al.  Mini Review Article , 2022 .

[33]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[34]  T. Marafioti,et al.  A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. , 2014, Blood.

[35]  C. Creighton,et al.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. , 2014, Blood.

[36]  Marcela V Maus,et al.  Antibody-modified T cells: CARs take the front seat for hematologic malignancies. , 2014, Blood.

[37]  M. Carroll,et al.  Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. , 2014, Blood.

[38]  J. Verhaagen,et al.  Developing a potentially immunologically inert tetracycline-regulatable viral vector for gene therapy in the peripheral nerve , 2014, Gene Therapy.

[39]  R. Brentjens,et al.  CD28z CARs and Armored CARs , 2014, Cancer journal.

[40]  Yongmin Tang,et al.  Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. , 2014, Cancer letters.

[41]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[42]  D. Bonnet,et al.  Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo , 2014, Leukemia.

[43]  D. Teachey,et al.  Toxicity management for patients receiving novel T-cell engaging therapies , 2014, Current opinion in pediatrics.

[44]  Shiu-Nan Chen,et al.  Apoptotic cell: linkage of inflammation and wound healing , 2014, Front. Pharmacol..

[45]  S. Gottschalk,et al.  Design and development of therapies using chimeric antigen receptor‐expressing T cells , 2014, Immunological reviews.

[46]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[47]  S. Riddell,et al.  Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma , 2013, PloS one.

[48]  Michel Sadelain,et al.  PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses , 2013, Science Translational Medicine.

[49]  L. Naldini,et al.  CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. , 2013, Blood.

[50]  Xiuli Wang,et al.  T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. , 2013, Blood.

[51]  N. Restifo,et al.  Reassessing target antigens for adoptive T cell therapy , 2013, Nature Biotechnology.

[52]  Hao Liu,et al.  Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition , 2013, Clinical Cancer Research.

[53]  Y. Kew,et al.  Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  P. Darcy,et al.  Gene-engineered T cells for cancer therapy , 2013, Nature Reviews Cancer.

[55]  Matthew L Baker,et al.  TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy , 2013, Molecular therapy. Nucleic acids.

[56]  D. Teachey,et al.  Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017-4023. , 2016, Blood.

[57]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[58]  B. Levine,et al.  T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans , 2013, Cancer Immunology Research.

[59]  Raphael Sandaltzopoulos,et al.  Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo , 2013, Cancer Immunology Research.

[60]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[61]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[62]  Tongguang Wang,et al.  Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy , 2013, Journal of immunotherapy.

[63]  Michel Sadelain,et al.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.

[64]  A. Biondi,et al.  Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. , 2012, Human gene therapy methods.

[65]  Navneeta Bansal,et al.  Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies , 2012, Clinical Cancer Research.

[66]  Takashi Saito,et al.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 , 2012, The Journal of experimental medicine.

[67]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[68]  Jinjuan Wang,et al.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. , 2012, Blood.

[69]  S. Eccles,et al.  Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling , 2012, Journal of Clinical Immunology.

[70]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[71]  D. Powell,et al.  A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. , 2012, Cancer research.

[72]  S. Rosenberg,et al.  Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice , 2012, Clinical Cancer Research.

[73]  Martin Pule,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[74]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[75]  Adrian P Gee,et al.  Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.

[76]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[77]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[78]  Hao Liu,et al.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.

[79]  S. Rosenberg,et al.  Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. , 2011, Cancer research.

[80]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  W. Burns,et al.  Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. , 2011, Blood.

[82]  C. Rooney,et al.  Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b , 2010, Journal of immunotherapy.

[83]  M. Tokunaga,et al.  Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. , 2010, Immunity.

[84]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[85]  M. Sadelain,et al.  IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. , 2010, Blood.

[86]  H. Heslop,et al.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety , 2010, Leukemia.

[87]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[88]  M. Sadelain,et al.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[89]  Thomas M. Schmitt,et al.  T cell receptor gene therapy for cancer. , 2009, Human gene therapy.

[90]  M. Kester,et al.  Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy , 2009, Haematologica.

[91]  D. Campana,et al.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[92]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[93]  H. Heslop,et al.  T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. , 2009, Blood.

[94]  Carsten Reinhardt,et al.  Bispecific T-cell engaging antibodies for cancer therapy. , 2009, Cancer research.

[95]  T. Schumacher,et al.  TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008 , 2009, Cancer Immunology, Immunotherapy.

[96]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[97]  D. Bigner,et al.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. , 2008, Seminars in immunology.

[98]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[99]  S. Rosenberg,et al.  Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. , 2007, The Journal of clinical investigation.

[100]  C. Bordignon,et al.  The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. , 2007, Blood.

[101]  C. Bordignon,et al.  Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. , 2007, Blood.

[102]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[103]  H. Vié,et al.  Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. , 2006, Blood.

[104]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  S. Rosenberg,et al.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells , 2005, The Journal of experimental medicine.

[106]  H. Heslop,et al.  An inducible caspase 9 safety switch for T-cell therapy. , 2005, Blood.

[107]  F. Ginhoux,et al.  HLA-A*0201-restricted cytolytic responses to the rtTA transactivator dominant and cryptic epitopes compromise transgene expression induced by the tetracycline on system. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[108]  D. Campana,et al.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia , 2004, Leukemia.

[109]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[110]  A. Mahfoudi,et al.  Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. , 2002, Human gene therapy.

[111]  B. Seliger,et al.  Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3ζ Signaling Receptor Molecule1 , 2001, The Journal of Immunology.

[112]  B. Seliger,et al.  T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. , 2001, Cancer research.

[113]  T. Barbui,et al.  Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. , 2000, Human gene therapy.

[114]  Shannon R. Magari,et al.  Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[115]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  L. Ginaldi,et al.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias. , 1998, Journal of clinical pathology.

[117]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[118]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[119]  C. Bonini,et al.  Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects. , 2016, Biochimica et biophysica acta.

[120]  Feng Yu,et al.  Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[121]  G. Efimov,et al.  Interleukin-6: From molecular mechanisms of signal transduction to physiological properties and therapeutic targeting , 2015, Molecular Biology.

[122]  Dario Campana,et al.  T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. , 2014, Cancer research.

[123]  R. Hawkins,et al.  Overcoming the toxicity hurdles of genetically targeted T cells , 2014, Cancer Immunology, Immunotherapy.

[124]  Takashi Saito,et al.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP 2 , 2012 .

[125]  T. Eberlein.  Durable Complete Responses in Heavily Pretreated Patients with metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2012 .

[126]  P. Darcy,et al.  Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. , 2011, Immunotherapy.

[127]  S. Forman,et al.  Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. , 2006, Cytotherapy.

[128]  E. McCarthy.  The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. , 2006, The Iowa orthopaedic journal.

[129]  E. Klein,et al.  Cancer immunotherapy: are the results discouraging? Can they be improved? , 1992, Advances in cancer research.

[130]  F. Burnet.  The concept of immunological surveillance. , 1970, Progress in experimental tumor research.

[131]  H. Lawrence.  Cellular and humoral aspects of the hypersensitive states : a symposium held at the New York academy of medicine , 1959 .